Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: The higher number of cases and deaths caused by COVID-19 in Colombia occurred during the third epidemic peak, where the Mu variant was associated with 50% of the cases.
OBJECTIVE: To evaluate the association between the clinical outcome of COVID-19 with health conditions and SARS-CoV-2 lineages.
METHODS: In this study, clinical metadata and SARS-CoV-2 lineages from 535 patients with different degrees of COVID-19 severity were obtained after the SARS-CoV-2 genomic surveillance in Colombia. Then, the associations between these variables were determined using a multidimensional unfolding analysis.
RESULTS: Asymptomatic, symptomatic, severe, and deceased outcomes represented 15.2%, 29.7%, 7.3%, and 47.8% of the cases, respectively. Males tend to develop more serious COVID-19, and severe or fatal outcomes were typically observed in patients aged >60 years with comorbidities, including chronic obstructive pulmonary disease, heart disease, kidney disease, obesity, asthma, and smoking history. The SARS-CoV-2 Mu and Gamma variants dominated the third epidemic peak and accounted for most fatal cases with odd ratio values of 128.2 (CI 53.0-310.1) and 18.6 (CI 8.294-41.917).
CONCLUSION: This study shows the high impact of SARS-CoV-2 lineages with higher prevalence on public health and the importance of monitoring COVID-19 risk factors to control the associated mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:125 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 125(2022) vom: 01. Dez., Seite 149-152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Álvarez-Díaz, Diego A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 20.12.2022 Date Revised 22.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2022.10.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348467869 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348467869 | ||
| 003 | DE-627 | ||
| 005 | 20231226040307.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.10.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348467869 | ||
| 035 | |a (NLM)36332905 | ||
| 035 | |a (PII)S1201-9712(22)00566-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Álvarez-Díaz, Diego A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes associated with Mu variant infection during the third epidemic peak of COVID-19 in Colombia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2022 | ||
| 500 | |a Date Revised 22.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: The higher number of cases and deaths caused by COVID-19 in Colombia occurred during the third epidemic peak, where the Mu variant was associated with 50% of the cases | ||
| 520 | |a OBJECTIVE: To evaluate the association between the clinical outcome of COVID-19 with health conditions and SARS-CoV-2 lineages | ||
| 520 | |a METHODS: In this study, clinical metadata and SARS-CoV-2 lineages from 535 patients with different degrees of COVID-19 severity were obtained after the SARS-CoV-2 genomic surveillance in Colombia. Then, the associations between these variables were determined using a multidimensional unfolding analysis | ||
| 520 | |a RESULTS: Asymptomatic, symptomatic, severe, and deceased outcomes represented 15.2%, 29.7%, 7.3%, and 47.8% of the cases, respectively. Males tend to develop more serious COVID-19, and severe or fatal outcomes were typically observed in patients aged >60 years with comorbidities, including chronic obstructive pulmonary disease, heart disease, kidney disease, obesity, asthma, and smoking history. The SARS-CoV-2 Mu and Gamma variants dominated the third epidemic peak and accounted for most fatal cases with odd ratio values of 128.2 (CI 53.0-310.1) and 18.6 (CI 8.294-41.917) | ||
| 520 | |a CONCLUSION: This study shows the high impact of SARS-CoV-2 lineages with higher prevalence on public health and the importance of monitoring COVID-19 risk factors to control the associated mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Genomic surveillance | |
| 650 | 4 | |a Lineage | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Ruiz-Moreno, Hector A |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata-Bedoya, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Franco-Muñoz, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Laiton-Donato, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Ferro, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Sepulveda, Maria T Herrera |e verfasserin |4 aut | |
| 700 | 1 | |a Pacheco-Montealegre, Mauricio |e verfasserin |4 aut | |
| 700 | 1 | |a Walteros, Diana M |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero-Galindo, Laura C |e verfasserin |4 aut | |
| 700 | 1 | |a Mercado-Reyes, Marcela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 125(2022) vom: 01. Dez., Seite 149-152 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:125 |g year:2022 |g day:01 |g month:12 |g pages:149-152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2022.10.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 125 |j 2022 |b 01 |c 12 |h 149-152 | ||